Tapestry saw an improvement in its IBD SmartSelect Composite Rating Friday, from 93 to 97. Please watch the video at ...

Growth has surged for road construction firm Construction Partners. Several heavy construction plays are just below buy ...

We provide a methodology for selecting high-growth dividend stocks, focusing on dividend growth and sustainability rather ...

Sean Casey, who most recently served as Community Leader, will transition to the role of Head of Operations and Development ...

IBD 50 gold names we currently own This gold ... overseas institutions sold a combined net of approximately $90 billion. Retail Investors Still Missing Out On The Gold Rally Despite the rally ...

We recently published a list of 13 Best Cheap Stocks to Invest in for Beginners. In this article, we are going to take a look ...

With the expansion of the digital asset landscape, individuals' ability to gain exposure to this asset class within their portfolio is increasing. Last week, four ETF issuers, CI Asset Management, ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Spyre Therapeutics, Inc.’s SYRE share price has dipped by 5.11%, which has investors questioning if this is right time to buy ...

Immunic's lead asset, vidofludimus calcium, shows promise in MS trials, with positive interim results. See why I rate IMUX stock a strong buy.

(RTTNews) - Spyre Therapeutics, Inc. (SYRE), a clinical-stage biotech company focused on innovative antibody therapies for Inflammatory Bowel Disease or IBD and related immune disorders ...